Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
AssigneePhigenix, Inc.
InventorCarlton D. DONALD
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
Claims23
A method for treating a prostate condition in a subject, comprising:
- administering to the subject an effective amount of a pharmaceutical composition comprising:
- a first agent that inhibits Engrailed-2 (EN2) expression and/or EN2 activity;
- and
- a second agent that inhibits PAX2 expression and/or PAX2 activity.
4-5. (canceled)
A method of treating prostate cancer or PIN in a subject, comprising administering to the prostate tissue of said subject an effective amounts of a pharmaceutical composition comprising:
- a first agent that reduces expression and/or activity of EN2;
- a second agent that enhance the expression and/or DEFB 1 activity;
- and
- a pharmaceutically acceptable carrier.
A method for treating prostate cancer or prostatic intraepithelial neoplasia (PIN) in a subject, comprising:
- (a) determining expression levels of EN2, PAX2 and DEFB1;
- (b) determining a PAX2-to-DEFB1 expression ratio in a diseased prostate tissue from the subject;
- (c) based on the results of (a) and (b), administering to said subject (1) an effective amounts of an agent that inhibits EN2 expression and/or EN2 activity and (2) an agent that inhibits PAX2 expression and/or PAX2 activity, and/or an agent that enhances expression and/or DEFB1 activity.
A pharmaceutical composition for treating prostate cancer or PIN, comprising:
- (1) an agent that inhibits EN2 expression and/or EN2 activity;
- and
- (2) an agent that inhibits PAX2 expression and/or PAX2 activity, and/or an agent that enhances expression and/or DEFB 1 activity.
Dependencies are inferred from the claim text.